Marietta Investment Partners LLC Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Marietta Investment Partners LLC purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 28,242 shares of the biopharmaceutical company’s stock, valued at approximately $1,479,000.

Other institutional investors have also modified their holdings of the company. Principal Securities Inc. bought a new stake in Halozyme Therapeutics during the 4th quarter valued at $34,000. Dimensional Fund Advisors LP increased its stake in Halozyme Therapeutics by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after buying an additional 145,879 shares during the period. Janney Montgomery Scott LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $473,000. Norges Bank bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $44,935,000. Finally, Coldstream Capital Management Inc. acquired a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $256,000. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, CFO Nicole Labrosse sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at $803,876.40. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $51.93, for a total value of $519,300.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at approximately $803,876.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the sale, the director now directly owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The disclosure for this sale can be found here. Insiders have sold 84,881 shares of company stock worth $4,888,184 in the last 90 days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Down 0.4 %

NASDAQ HALO opened at $59.24 on Monday. The firm’s 50 day moving average price is $58.40 and its two-hundred day moving average price is $49.25. The stock has a market cap of $7.54 billion, a price-to-earnings ratio of 24.48, a PEG ratio of 0.57 and a beta of 1.28. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $65.53. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.68 earnings per share. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current year.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research analyst reports. The Goldman Sachs Group upped their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and increased their target price for the company from $48.00 to $51.00 in a research note on Friday, June 7th. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a research report on Friday, September 13th. Morgan Stanley upped their price target on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. Finally, Benchmark reissued a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.00.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.